GHK-Cu
A naturally occurring copper-binding tripeptide (Glycyl-L-Histidyl-L-Lysine) found in human plasma and first isolated from serum albumin fractions in 1973. The strongest human evidence supports topical dermatological applications — skin aging and wound care — where multiple controlled studies have been conducted. Injectable or systemic use represents a distinct and substantially less evidenced category; its systemic safety profile is not established, and injectable formulations were removed from US compounding eligibility in 2026.
Side effects & risks
GHK-Cu has not been evaluated in large-scale, randomised controlled trials of systemic administration in humans. The risk profile for injectable or systemic use is, in practical terms, unknown.
Copper-containing compounds carry an inherent concern regarding copper accumulation with repeated systemic exposure. Elevated systemic copper is associated with toxicity; Wilson's disease and other conditions of copper dysregulation represent the clearest clinical examples of copper-mediated harm. Whether the doses of GHK-Cu discussed in community contexts would materially elevate systemic copper has not been studied in humans.
For topical cosmetic application, GHK-Cu has an extensive commercial history across skincare products. Adverse event reports in cosmetic use are rare in the published literature, with skin irritation and contact sensitisation described in isolated cases. The safety profile of cosmetic topical use does not extrapolate to systemic injection.
Pickart and Margolina (2018, Cosmetics, vol. 5, no. 2; open access) reviewed GHK-Cu's biological activity and noted the compound's long history of cosmetic use without widespread reported adverse events at typical cosmetic concentrations. This review was co-authored by Loren Pickart, who has commercial interests in GHK-Cu research and products; readers should weigh this context when evaluating the conclusions.
Community reports of systemic use describe skin flushing, mild headache, and localised skin changes at injection sites. Causality and frequency are not established. GHK-Cu is not approved for human therapeutic use as an injectable in any major regulatory jurisdiction.
Evidence summary
Latest studies
A tea exosome-integrated self‑oxygenating cascade chitosan/oxidized alginate hydrogel for remodeling the hyperglycemic and hypoxic microenvironment in diabetic wound healing.
Diabetic wounds are hard to close because high sugar, infection, and low oxygen keep the tissue in a damaged state. Chinese researchers built an injectable gel dressing that chains several ingredients together: an enzyme eats the excess glucose and turns it into a germ-killing compound, and the copper peptide GHK-Cu then converts that compound into oxygen for the starved tissue, while tea-leaf-derived particles calm the immune response. In lab dishes and in animals, the gel curbed bacteria, boosted new blood-vessel growth, and markedly sped up wound closure. This is early-stage materials research, not a product tested in people.
Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury.
Radiotherapy for cancer can damage the skin because it generates harmful reactive oxygen molecules and triggers inflammation. This study developed a smart injectable gel to address that. The gel was made by linking two natural materials (a modified chitosan and oxidised hyaluronic acid) together with the copper peptide GHK-Cu, and it also contained tiny carbon particles that mimic an antioxidant enzyme. The gel was designed to release its components in stages: in the acidic environment of a wound, the carbon particles are released quickly to neutralise harmful oxygen molecules and calm early damage, after which GHK-Cu is released slowly to support tissue repair by easing inflammation, helping cells move and multiply, and encouraging collagen formation. In laboratory and animal tests, the gel reduced radiation-related oxidative damage and inflammation and helped skin wounds heal faster. Because GHK-Cu was only one part of a multi-component system, its individual role cannot be separated out. This was cell and animal research; human data would be needed before drawing any medical conclusions.
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
This narrative review gathers what is currently known about several regenerative peptides — BPC-157, thymosin beta-4/TB-500, GHK-Cu and related compounds — in the context of long-term pain management and tissue repair. The authors describe proposed mechanisms and safety profiles, then conclude that human clinical evidence is still thin. Most of these compounds are not FDA-approved for these uses.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“cjc 1295 (NO DAC) + ipamorelin and GHK-Cu”
A user asks about combining CJC-1295 (no DAC) and Ipamorelin with GHK-Cu, likely seeking input on whether the GH-secretagogue stack and the copper peptide make sense together and how each is dosed.
“IGH 1-LR3, glutathione, CJC-1295 IPAMORELIN, klow stack”
A multi-compound stack thread covering IGF-1 LR3, glutathione, the CJC-1295 plus Ipamorelin combo, and the KLOW blend (KPV, GHK-Cu, BPC-157, TB-500), likely asking how to sequence or dose the full protocol.
“5 month GHK-Cu Update!”
A five-month personal progress update on GHK-Cu use, sharing the poster's ongoing experience with the copper peptide over an extended timeframe for others following similar protocols.
“GHK-CU is the real deal!”
A second same-week r/Biohacking thread reporting strong satisfaction with GHK-Cu, reinforcing a cluster of positive user sentiment around the copper peptide; specifics of use and outcomes remain anecdotal.
“Ghk-cu is the goat peptide”
An enthusiastic endorsement thread praising GHK-Cu, part of a visible wave of positive GHK-Cu anecdotes in biohacking communities this week; the strong framing is anecdotal and unaccompanied by controlled evidence.
Reported protocols (with caveats)
| USE | ROUTE | COMMON DOSE | FREQUENCY | TYPICAL CYCLE |
|---|---|---|---|---|
| Topical skin care | Topical application | 0.1–3% concentration | 1–2× daily | Ongoing |
| Systemic (community-reported) | SC injection | 1–2 mg | Daily to several times weekly | Not established |
Frequently asked questions
- What are the known risks of GHK-Cu?
- The risk profile for injectable systemic use of GHK-Cu is unknown; no large-scale human safety data exists. A specific theoretical concern is copper accumulation with repeated systemic dosing, since elevated copper is associated with toxicity. The well-documented cosmetic topical use does not translate to safety of injection. Community reports of systemic use mention flushing, headache, and injection-site reactions. GHK-Cu is not approved for human therapeutic injection use in any major jurisdiction.
- How is GHK-Cu different from other copper peptides?
- GHK-Cu is the most extensively researched copper peptide in the published literature. It consists of three amino acids — glycine, histidine, and lysine — chelating a copper(II) ion. Other copper peptide complexes exist (e.g. AHK-Cu), but GHK-Cu is the compound for which most published cell-culture and animal data exists. These compounds are related but distinct; research findings from one cannot be assumed to apply to another.
- Does GHK-Cu have human clinical trial evidence?
- For topical cosmetic applications, there are small-scale clinical studies showing improvements in skin parameters. For systemic injectable use — the form most discussed in peptide research communities — no peer-reviewed, controlled human clinical trial data has been published as of mid-2026. The body of evidence is predominantly cell culture and animal model data.
- What is GHK-Cu believed to do in the body?
- In cell culture studies, GHK-Cu has been associated with upregulation of collagen synthesis in fibroblast cultures (Maquart et al., 1988, FEBS Letters; PMID 3169264), as well as reported modulation of a broad set of genes involved in inflammation, wound healing, and tissue remodelling. These mechanisms have not been confirmed in adequately powered human clinical trials. The compound's naturally declining plasma concentration with age has led to hypotheses about potential roles in biological aging, which remain speculative.
- Is GHK-Cu legal to buy or use?
- As an ingredient in cosmetic skincare products, GHK-Cu is widely available and legal in most markets. As a research chemical for systemic injection, it is not approved for human therapeutic use in the United States, Australia, Canada, the UK, or most of the EU. The FDA removed GHK-Cu from its Category 2 compounding list (~April 2026), meaning it can no longer be legally compounded by 503A/503B pharmacies in the US. Regulatory status varies by jurisdiction and intended use category; verify current status with a qualified legal or clinical professional.